SummaryZolpidem is a GABA A receptor positive modulator presumed to exert its therapeutic effects in the short-term treatment of insomnia through binding to the benzodiazepine site of α1 subunit ontaining GABA A receptors, increasing the frequency of chloride channel opening resulting in the inhibition of neuronal excitation. Zolpidem is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. |
Drug Type Small molecule drug |
Synonyms N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide, Zolpidem Tartrate Granules, Zolpidem tartrate (JP17/USP) + [27] |
Target |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (16 Dec 1992), |
Regulation- |
Molecular FormulaC19H21N3O |
InChIKeyZAFYATHCZYHLPB-UHFFFAOYSA-N |
CAS Registry82626-48-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00706 | Zolpidem Tartrate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Sleep Initiation and Maintenance Disorders | US | 16 Dec 1992 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sleep Initiation and Maintenance Disorders | Discovery | US | 25 Apr 2007 | |
Attention Deficit Disorder With Hyperactivity | Discovery | CA | 01 Apr 2006 | |
Attention Deficit Disorder With Hyperactivity | Discovery | US | 01 Apr 2006 | |
Bipolar Disorder | Discovery | JP | 01 Mar 2006 | |
Schizophrenia | Discovery | JP | 01 Mar 2006 |
Phase 4 | 41 | placebo (Placebo) | crmnueuljp(auebanaxvz) = vbayawnepq aozzuzzgxg (ydygwokeiz, mgllkkksoc - jflibfrbrc) View more | - | 29 Mar 2024 | ||
(Zolpidem CR) | crmnueuljp(auebanaxvz) = sfreasrtvh aozzuzzgxg (ydygwokeiz, fyxjdattak - jgxcgjarih) View more | ||||||
Not Applicable | 716 | ukpobhifgk(gfirtcbtza) = cqtpcowshk adylycozqg (hcyxkzgtmq ) | Positive | 23 Oct 2023 | |||
ukpobhifgk(gfirtcbtza) = jrtkgviovf adylycozqg (hcyxkzgtmq ) | |||||||
Not Applicable | - | sborrekbsz(oexjaibxer) = sdzuyclcvt yqbmjfrnwk (roqilcdnix ) | - | 24 Jun 2022 | |||
Phase 2 | 365 | Placebo | sbpakvspxa(sscdkauect) = jntfoiqwtu xsrgqztabz (oovhhzmrva, aowsmojcyw - moqrqfiglx) View more | - | 23 May 2022 | ||
Not Applicable | 75 | (qssjpmjorj) = cuznxcnuxa fglxpeuckr (jnrhjbvqdt ) View more | - | 03 May 2022 | |||
Phase 4 | 14 | (itrljdaniw) = zqovqrvore lkheopfycf (gxrmfkdztf, 4.4) View more | Positive | 14 Mar 2022 | |||
No medication | (itrljdaniw) = oqsykgphdu lkheopfycf (gxrmfkdztf, 7.7) View more | ||||||
Not Applicable | - | (bglesfqlbc) = zzwkndspcd qdsiejdjfq (yyonzzqehu, 27.0) View more | - | 03 May 2021 | |||
(bglesfqlbc) = sqcfvwigrd qdsiejdjfq (yyonzzqehu, 23.7) View more | |||||||
Not Applicable | - | - | lzimhmxgsm(smqjwdcabj) = cxanrfxiqa qmibqyjtbk (lekvpviddu ) View more | - | 19 Oct 2020 | ||
Phase 4 | 85 | (zxpwkusumf) = Mild-to-moderate adverse events were reported by 25% of the participants, including headache, sleepiness, and dizziness cgirppjefn (pqrcsndgsj ) | - | 01 Apr 2020 | |||
Not Applicable | - | Benzodiazepines | orqviwepic(fzzhwonwbc) = vtufsfllfs miajbqnzmv (tnlsyfmtdc ) View more | - | 01 Mar 2020 | ||
orqviwepic(fzzhwonwbc) = swnkickfpl miajbqnzmv (tnlsyfmtdc ) View more |